

Kairos Pharma, Ltd. (KAPA)

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001962011

Kairos Pharma, Ltd. KAPA; healthcare		
Grade	None 2 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025	
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	under \$12.5M assets total assets \$6.5M	
Warnings	late filer, thin data not computable: dilution, degenerate inputs, distress, fortress balance sheet	
Inputs computable	2 of 14	
Graded from	filings received through Mar 31, 2026 192 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026	
Last close	\$0.93 2026-10-08; market equity \$22.0M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies mission is to advance our portfolio of innovative therapeutics to target key mechanisms of therapeutic resistance and immune suppression and transform the way cancer is treated.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 13.5						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(32.6%)	(6.6%)	13.5	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 2.0						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		not computable	(0.31)			latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		27.07x	2.96x	2.0	839	2025-12-31
Growth and financing						
Revenue growth, three-year compound		not computable	10.0%			four annual observations are required; found 0
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 0
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		not computable	2.1%			four annual observations are required; found 2
Net share issuance, one year		not computable	2.5%			prior share count is 246 days earlier

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Thin data	2 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	43.6%	8.0%	72
Distance from 52-week high	(59.8%)	(31.4%)	18
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.18	0.28	38
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	0.15	(0.14)	72

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$2.6M
Operating cash flow, four quarters	-\$4.0M
Months of runway	7.9
Days since last periodic filing	58 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	\$135,994

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$5.4M	2025-12-31	2026-03-31	10-K	0001493152-26-014159
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$3.4M	2025-12-31	2026-03-31	10-K	0001493152-26-014159
3	assets	us-gaap:Assets	\$6.5M	2025-12-31	2026-03-31	10-K	0001493152-26-014159
4	assets	us-gaap:Assets	\$5.8M	2024-12-31	2026-03-31	10-K	0001493152-26-014159
5	current assets	us-gaap:AssetsCurrent	\$4.2M	2024-12-31	2026-03-31	10-K	0001493152-26-014159
6	current liabilities	us-gaap:LiabilitiesCurrent	\$992,000	2024-12-31	2026-03-31	10-K	0001493152-26-014159
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$8.8M	2024-12-31	2026-03-31	10-K	0001493152-26-014159
8	operating income	us-gaap:OperatingIncomeLoss	-\$2.3M	2024-12-31	2026-03-31	10-K	0001493152-26-014159
9	book equity	us-gaap:StockholdersEquity	\$4.8M	2024-12-31	2026-03-31	10-K	0001493152-26-014159
10	liabilities	us-gaap:Liabilities	\$992,000	2024-12-31	2025-04-15	10-K	0001641172-25-004920
11	current assets	us-gaap:AssetsCurrent	\$5.4M	2025-12-31	2026-03-31	10-K	0001493152-26-014159
12	current liabilities	us-gaap:LiabilitiesCurrent	\$199,000	2025-12-31	2026-03-31	10-K	0001493152-26-014159
13	shares outstanding	dei:EntityCommonStockSharesOutstanding	21,411,198	2026-03-31	2026-03-31	10-K	0001493152-26-014159
14	shares outstanding	dei:EntityCommonStockSharesOutstanding	20,457,480	2025-07-28	2025-07-28	10-K/A	0001641172-25-021134